Alexandre TerrierExpertise
BiomechanicsJoint biomechanicsMecano-biologyOrthopaedic researchPatient-specific modellingContinuum mechanicsFinite Element AnalysisExperimental testingStatistical analyses
Expertise
BiomechanicsJoint biomechanicsMecano-biologyOrthopaedic researchPatient-specific modellingContinuum mechanicsFinite Element AnalysisExperimental testingStatistical analyses
Mission
Develop patient-specific models of human joints and their replacement, in parallel with a database of patients, in order to test statistic
Mohamed FarhatM. Farhat was born in Casablanca in 1962 (Moroccan citizen). He graduated at Ecole Nationale Supérieure d'Hydraulique et de Mécanique de Grenoble (France. He joined The LMH laboratory in 1986 as research assistant. He completed in 1994 a Ph.D. thesis on Cavitation. He joined the R&D department of Hydro-Quebec in Montréal (Canada) in 1995 where he was in charge of several research projects in the areas of production and transportation of hydropower and mainly the monitoring of large hydro turbines. Since 2001, he is senior scientist at the LMH laboratory, head of the cavitation group. He is also lecturer in Master and Doctoral programs. He is member of the Doctoral Committee in Mechanics.
Christophe MoserDr. Christophe Moser is
Associate Professor of Microengineering and Industrial Relations
at the Swiss Federal Institute of Technology in Lausanne. He was the co-founder and CEO of
Ondax,Inc
for ten years prior to joining EPFL. During this decade, he raised $15 million from corporate and venture capital sources to fund volume production of thick holographic components in glass and develop devices enabled by these components such as tunable add-drop multiplexers for telecommunications, ultra-narrowband notch filters for low frequency Raman systems, high power semi-conductor frequency-narrowed pumps for fiber lasers, single frequency fixed and tunable lasers for sensing and femtosecond pulse compressors for micro-machining applications. Dr. Moser has a Ph.D. in Electrical Engineering from the California Institute of Technology, a minor in finance and a bachelor degree in Physics from EPFL.
He is the co-inventor of 24 patents, 14 peer reviewed scientific publications, 9 IEEE proceedings and a book chapter.
Private interests include tennis, running, ski, basketball and family excursions.
2010: Associate Professor, EPFL, faculty
Science Technique Ingenieur.
2000-2010: co-founder, CEO Ondax, Inc.
1995-2000: Graduate Research Assistant,
California Institute of Technology.
1993-1995: Engineering Project manager ,
TESA.
1988-1993: Bachelor candidate in Physics, EPFL.
MAIN PUBLICATIONS:
Moser C., Havermeyer F,.Ultra-narrowband tunable laserline notch filter, Appl. Phys. B, 95 (3), pp 597-601, 2009.
Moser C. ,Ho L., Havermeyer F,. Self-aligned Non-dispersive External Cavity Tunable Laser, 16 (21), 16691-16696 Optics Express, 2008.
Steckman, GJ , Moser C. et al. Volume holographic grating wavelength stabilized laser diodes, IEEE J. Of Selected Topics in Quantum Electronics, (13), 672-678, 2007.
Buse K, Havermeyer F, Liu W., Moser C, Psaltis D. Holographic Filters , Book Chapter Photorefractive Materials and their Applications, 2005.
Havermeyer, F; Liu, WH; Moser, C, et al. Volume holographic grating-based continuously tunable optical filter , Opt. Eng. 43 (9), 2017-2021, 2004.
Moser C., Maravic I., Schupp B., Adibi A, Psaltis D, Diffraction efficiency of localized holograms in doubly doped LiNbO3 crystals, Opt. Lett. 25: (17),1243-1245, 2000. Dominique PiolettiDominique Pioletti received his Master in Physics from the Swiss Federal Institute of Technology Lausanne (EPFL) in 1992. He pursued his education in the same Institution and obtained his PhD in biomechanics in 1997. He developed original constitutive laws taking into account viscoelasticity in large deformations. Then he spent two years at UCSD as post-doc fellow acquiring know-how in cell and molecular biology. He was interested in particular to gene expression of bone cells in contact to orthopedic implant. In April 2006, Dominique Pioletti was appointed Assistant Professor tenure-track at the EPFL and is director of the Laboratory of Biomechanical Orthopedics. His research topics include biomechanics and tissue engineering of musculo-skeletal tissues; mechano-transduction in bone; development of orthopedic implant as drug delivery system. Since 2013, he has been promoted to the rank of Associate Professor.
Nikolaos StergiopoulosEducation
MTE, Managing the Technology Enterprise Program (2000), IMD, Lausanne
Ph.D. in Biomedical Engineering & Engineering Mechanics (1990) Iowa State University, Ames, Iowa.
MS in Biomedical Engineering (1987) Iowa State University, Ames, Iowa.
Diploma in Mechanical Engineering (1985) National Technical University of Athens.
Professional Activities
2002 - present: Professor and director of LHTC
2010 - present: Founder and director of Rheon Medical SA, Préverenges, Switzerland
2008 - present: Founder and director of Antlia S.A., PSE-C, EPFL campus, Switzerland
1998 - 2007: Founder and Scientific Director of EndoArt S.A., Lausanne, Switzerland
1996 - 2002: Assistant professor at the Biomedical Engineering Laboratory, Swiss Federal Institute of Technology, Lausanne, Switzerland.
1991 - 1996: Research Associate at Swiss Federal Institute of Technology - Lausanne
1990 - 1991: Lecturer, Iowa State University
Georges WagnièresGeorges Wagnières received his diploma degree (MSc) in physics from the University of Lausanne, Switzerland, in 1986. He obtained his doctorate in science (PhD) in physics (Biomedical optics) from the Swiss Federal Institute of Technology at Lausanne (EPFL) in 1992 and did a postdoctoral work in the Wellman Laboratories of Photomedicine (Harvard Medical School), Boston, USA, from 1993 to 1994. He also obtained a Master degree in Management of Technology delivered by the Ecole des Hautes Etudes Commerciales (HEC) of Lausanne University and the EPFL in 2001. Georges Wagnières manages a research group active in the fields of: - Detection of early superficial cancers by fluorescence imaging. - Characterization of early superficial cancers by high magnification narrow band imaging. - In vivo and in vitro measurement of the vascular and tissular oxygen concentration by time-resolved luminescence spectroscopy and imaging. - Preclinical and clinical study of new photosensitizers for photodynamic therapy (PDT). - Treatment of neurodegenerative conditions (Alzheimer, Parkinson's diseases) by photobiomodulation. - Preclinical and clinical photodynamic therapy of inflammatory bowel diseases and atheroscerotic plaque. - Improvement of the selective vascular extravasation of chemotherapeutic agents by PDT. - Monitoring the light dosimetry during PDT by fluorescence spectroscopy and imaging. - Monitoring laser treatments of the retina by reflectance imaging. - Light dosimetry and tissue optical spectroscopy. - Radiometry. - Development of light delivery systems for biomedical applications. Georges Wagnières is also co-founder and was chairman of one spin-off companies: - Medlight SA, founded in July 1997, which develops, produces and commercializes light distributors for photodynamic therapy. Georges Wagnières has currently authored more than 235 papers (more than 150 in international journals with review board) and is inventor of 18 patents. He supervised 12 PhD students up to now, and currently teaches biomedical optics and photomedicine in master programs and doctoral schools. In addition, he gives the course entitled "Physique Générale I" to biology first year students registered to the Biology School of the Lausanne's University. MAIN PUBLICATIONS Please visit: https://www.epfl.ch/labs/lifmet/wagnieres/publications/ Johan AuwerxJohan Auwerx is Professor at the École Polytechnique Fédérale in Lausanne, Switzerland, where he occupies the Nestle Chair in Energy Metabolism. Dr. Auwerx has been using molecular physiology and systems genetics to understand metabolism in health, aging and disease. Much of his work focused on understanding how diet, exercise and hormones control metabolism through changing the expression of genes by altering the activity of transcription factors and their associated cofactors. His work was instrumental for the development of agonists of nuclear receptors - a particular class of transcription factors - into drugs, which now are used to treat high blood lipid levels, fatty liver, and type 2 diabetes. Dr. Auwerx was amongst the first to recognize that transcriptional cofactors, which fine-tune the activity of transcription factors, act as energy sensors/effectors that influence metabolic homeostasis. His research validated these cofactors as novel targets to treat metabolic diseases, and spurred the clinical use of natural compounds, such as resveratrol, as modulators of these cofactor pathways.
Johan Auwerx was elected as a member of EMBO in 2003 and is the recipient of a dozen of international scientific prizes, including the Danone International Nutrition Award, the Oskar Minkowski Prize, and the Morgagni Gold Medal. His work is highly cited by his peers with a h-factor of over 100. He is an editorial board member of several journals, including Cell Metabolism, Molecular Systems Biology, The EMBO Journal, Journal of Cell Biology, Cell, and Science. Dr. Auwerx co-founded a handful of biotech companies, including Carex, PhytoDia, and most recently Mitobridge, and has served on several scientific advisory boards.
Dr. Auwerx received both his MD and PhD in Molecular Endocrinology at the Katholieke Universiteit in Leuven, Belgium. He was a post-doctoral research fellow in the Departments of Medicine and Genetics of the University of Washington in Seattle.
Rolf GruetterAwards:
1999 Young Investigator Award Plenary Lectureship
, International Society for Neurochemistry
2011 Fellow
, ESMRMB
2011 Teaching Award
, Section Sciences de la Vie, EPFL
Show more